Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT)

NCT ID: NCT06222788

Last Updated: 2024-06-27

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-09-30
• Study Completion Date: 2026-01-31

Brief Summary

The goal of this clinical trial is to test the safety of the use of non-thermal plasma (NTP, an ionized gas) on the tumor bed after the removal of the tumor in breast cancer patients. The main questions it aims to answer are:

• To determine the safe and tolerable dose of NTP in patients with breast cancer;
• To assess the safety and tolerability of NTP;
• To assess the cosmetic effects of NTP treatment in patients with breast cancer. Participants will receive one treatment of the tumor bed after the removal of their breast tumor.

Detailed Description

Non-thermal plasma (NTP) refers to an ionized gas composed of ions, electrons and other reactive agents. The anti-cancerous properties of NTP have been proven in vitro and in vivo. The 10-year local recurrence risk (LRR) in breast cancer patients after a breast conservation therapy (i.e., lumpectomy, typically followed by radiation therapy) is still as high as 15-20%. NTP could be used to further treat the tumor bed to reduce the LRR.

The primary objective of this clinical trial is to determine the safe and tolerable dose of NTP treatment following breast cancer lumpectomy. The secondary objectives are to assess the safety and tolerability of NTP and to assess the cosmetic effects of NTP treatment in patients with breast cancer. Our exploratory objective is to assess the impact of NTP treatment on cancerous and normal tissues. Patients are followed for 3 months after NTP treatment. The patients are divided into 3 groups: group A (n=3): NTP treatment of part of the tumor bed ex vivo. Group B (n=3): NTP treatment of part of the tumor bed in situ (all treated tissues are removed for analysis). Group C (n=6-24): dose escalation per "3+3 Design" up to a maximum dose level 3. NTP treatment of part of the tumor bed in situ (the treated parts of the tumor bed will not be excised, except a small portion for analysis).

The safety and tolerability of treatment will be evaluated by means of dose limiting toxicities, adverse events (AEs) and serious adverse events reports, physical examinations, and laboratory safety evaluations. AEs will be coded according to the CTCAE v5.0. The results will be tabulated to examine their frequency, grade, and relationship to study treatment. The results of laboratory assessments will be evaluated similarly. The number of patients with cosmetic alterations linked to the NTP treatment and type of alterations will be assessed through the quality of life questionnaires (questions on breast appearance and texture) and through the photo collection. This is the first clinical trail to study the safety and tolerability of NTP in an all breast-cancer patient group.

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

NTP treatment

The patients will be treated with NTP intra-operatively.

Group Type: EXPERIMENTAL

Convertible Plasma Jet

Intervention Type: DEVICE

NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)

Interventions

Convertible Plasma Jet

NTP will be applied to the patients using the Convertible Plasma Jet (CPJ, NexPlasmaGen Inc.)

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 years at the time of signing study consent.

2. ECOG ≤2.

3. Patient with T1-4 breast cancer for groups A and B; patient with T1/T2 breast cancer for group C (based on physical exam, not radiological measurements).

4. Patient is scheduled to undergo a lumpectomy.

Exclusion Criteria

1. Prior treatment for the tumor of interest (including chemotherapy, immunotherapy, radiotherapy).

2. Patient planning to or undergoing intraoperative radiotherapy.

3. Diabetes (types I and II).

4. Hypercortisolism.

5. Collagen vascular disease.

6. Patient requiring systemic corticosteroids at physiologic doses exceeding 10 mg/day of prednisone or its equivalent.

7. Patient receiving daily chemotherapy for rheumatological conditions.

8. Pregnancy (a urine pregnancy test must be obtained for non-sterile women of childbearing potential prior to surgery).

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Ozmosis Research Inc.

INDUSTRY

Sponsor Role: collaborator

Ministère de l'Économie, de l'Innovation et de l'Énergie, Québec, Canada

UNKNOWN

Sponsor Role: collaborator

Quebec Breast Cancer Foundation

OTHER

Sponsor Role: collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Centre Hospitalier de l'Université de Montréal - CHUM

Montreal, Quebec, Canada

Countries

Canada

Facility Contacts

Ana Lydia Tkalec

Role: primary

lydia.tkalec.chum@ssss.gouv.qc.ca

514-890-8000 ext. 14186

Audrey Glory, PhD

Role: backup

audrey.glory.chum@ssss.gouv.qc.ca

4389387119

References

Glory A, Patocskai E, Wong P. Breast cancer PAINT: a first-in-human, dose-escalation study to determine the safety of Plasma Adjuvant INtra-operative Treatment in breast cancer patients. BMC Cancer. 2025 Apr 22;25(1):748. doi: 10.1186/s12885-025-14153-5.

Reference Type: DERIVED

PMID: 40264065 (View on PubMed)

Other Identifiers

OZM-133

Identifier Type: OTHER

Identifier Source: secondary_id

2024-11512

Identifier Type: -

Identifier Source: org_study_id